Pub Date : 2024-09-07DOI: 10.1016/j.soi.2024.100097
Nathan A. Coppersmith , Kurt S. Schultz , Andrew C. Esposito , Kimberly Reinhart , Emily Ray , Ira L. Leeds , Haddon J. Pantel , Vikram B. Reddy , Walter E. Longo , Anne K. Mongiu
Low Anterior Resection Syndrome (LARS) is a syndrome of lifestyle-limiting defecatory dysfunction diagnosed after the treatment of rectal cancer that can afflict 41 % of patients one year after surgery. Currently, the treatment of LARS is reactionary to the development of symptoms, and post-treatment pelvic floor physical therapy (PFPT) is one form of treatment utilized to mitigate the symptoms of LARS and improve patient quality of life. Prehabilitation is the physical and/or lifestyle preparation that improves recovery following surgery. For rectal cancer patients, general prehabilitation while undergoing neoadjuvant chemoradiotherapy is safe and feasible. However, no studies have examined whether pelvic floor physical therapy prehabilitation, which we term “PrePFPT,” could mitigate the development of LARS. In this commentary, we argue that PrePFPT should become an active area of research in rectal cancer to improve functional and quality of life outcomes. We highlight two proposed international trials, which will evaluate pre- and postoperative PFPT as a strategy to reduce the incidence of LARS. We conclude with our own proposed PrePFPT study design.
低位前切除综合征(LARS)是一种在直肠癌治疗后被诊断出的限制生活方式的排便功能障碍综合征,41%的患者在术后一年会出现这种症状。目前,治疗 LARS 的方法是根据症状的发展作出反应,治疗后盆底物理治疗 (PFPT) 是减轻 LARS 症状和提高患者生活质量的一种治疗方法。术前康复是指在身体和/或生活方式上做好准备,以改善术后恢复。对于直肠癌患者来说,在接受新辅助放化疗的同时进行一般康复训练是安全可行的。然而,还没有研究探讨盆底物理治疗前康复(我们称之为 "PrePFPT")是否能减轻 LARS 的发生。在这篇评论中,我们认为盆底物理治疗前康复训练应成为直肠癌的一个积极研究领域,以改善功能和生活质量。我们重点介绍了两项拟议的国际试验,这两项试验将评估术前和术后 PFPT 作为降低 LARS 发生率的策略。最后,我们提出了自己的 PrePFPT 研究设计方案。
{"title":"Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome","authors":"Nathan A. Coppersmith , Kurt S. Schultz , Andrew C. Esposito , Kimberly Reinhart , Emily Ray , Ira L. Leeds , Haddon J. Pantel , Vikram B. Reddy , Walter E. Longo , Anne K. Mongiu","doi":"10.1016/j.soi.2024.100097","DOIUrl":"10.1016/j.soi.2024.100097","url":null,"abstract":"<div><p>Low Anterior Resection Syndrome (LARS) is a syndrome of lifestyle-limiting defecatory dysfunction diagnosed after the treatment of rectal cancer that can afflict 41 % of patients one year after surgery. Currently, the treatment of LARS is reactionary to the development of symptoms, and post-treatment pelvic floor physical therapy (PFPT) is one form of treatment utilized to mitigate the symptoms of LARS and improve patient quality of life. Prehabilitation is the physical and/or lifestyle preparation that improves recovery following surgery. For rectal cancer patients, general prehabilitation while undergoing neoadjuvant chemoradiotherapy is safe and feasible. However, no studies have examined whether pelvic floor physical therapy prehabilitation, which we term “PrePFPT,” could mitigate the development of LARS. In this commentary, we argue that PrePFPT should become an active area of research in rectal cancer to improve functional and quality of life outcomes. We highlight two proposed international trials, which will evaluate pre- and postoperative PFPT as a strategy to reduce the incidence of LARS. We conclude with our own proposed PrePFPT study design.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001063/pdfft?md5=1503e54387f16fc32d75bc1d4ded9c65&pid=1-s2.0-S2950247024001063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.soi.2024.100086
Haejin In , Alexandra Adams , Sammy Ho , Srawani Sarkar , Fei Wang , Aaron Oh , Dong Jun Yun , Atish Gandhi , Shengguo Li , Hao Liu , Douglas R. Morgan , Julie Yang
Background
Serum Pepsinogen (PG) and Helicobacter pylori (Hp) have potential as biomarkers to identify persons at high risk for gastric cancer (GC) in low incidence populations. We explored the use of these biomarkers in a diverse US population.
Methods
Single institution study using serum samples from 32 newly diagnosed GC (before treatment) and 60 non-cancer participants. ELISA-based PG-I, PG-II, Hp IgG, and Hp virulence seromarker (CagA, VacA) tests were conducted to examine differences between GC and non-GC participants.
Results
Median age was 58 (IQR 48–68); 56 % were females; 30.1 % were white, 14.8 % black, 28.7 % Hispanic, 6.1 % Asian and 18.2 % other/unknown race/ethnicity. Median values of Hp (47.9 vs 12.6 U/mL, p = 0.003) and pepsinogen ratio (PGR=PGI/PGII) (4.0 vs 7.5, p = 0.003) differed between GC and non-GC. Performance of pepsinogen tests using “standard” cut-offs (PGI ≤ 70 ng/mL and PGR ≤ 3) were highly specific (91.7 %), but not sensitive (34.4 %), while Hp IgG test using “standard” cut-off (≥ 30 U/mL) was sensitive (78.8 %), but less specific (41.2 %). Optimized cut-off values identified in our population using Youden’s Index were PGR ≤ 5.2 and Hp ≥ 17.5 U/mL. Using a combination of these values resulted in a significant increase in test sensitivity (87.9 %) with lower specificity (50.8 %).
Conclusion
The combination of pepsinogens and Hp show promise as biomarkers of GC risk in a racially and ethnically diverse US population. Optimal biomarker cut-off points for US populations may differ from those established in East Asia. By adjusting cut-offs there is potential to design GC risk stratification tools tailored specifically for the diverse population within the US.
{"title":"Pepsinogen and Helicobacter pylori: Serum biomarkers for gastric cancer risk in a diverse United States population","authors":"Haejin In , Alexandra Adams , Sammy Ho , Srawani Sarkar , Fei Wang , Aaron Oh , Dong Jun Yun , Atish Gandhi , Shengguo Li , Hao Liu , Douglas R. Morgan , Julie Yang","doi":"10.1016/j.soi.2024.100086","DOIUrl":"10.1016/j.soi.2024.100086","url":null,"abstract":"<div><h3>Background</h3><p>Serum Pepsinogen (PG) and <em>Helicobacter pylori</em> (Hp) have potential as biomarkers to identify persons at high risk for gastric cancer (GC) in low incidence populations. We explored the use of these biomarkers in a diverse US population.</p></div><div><h3>Methods</h3><p>Single institution study using serum samples from 32 newly diagnosed GC (before treatment) and 60 non-cancer participants. ELISA-based PG-I, PG-II, <em>Hp</em> IgG, and <em>Hp</em> virulence seromarker (CagA, VacA) tests were conducted to examine differences between GC and non-GC participants.</p></div><div><h3>Results</h3><p>Median age was 58 (IQR 48–68); 56 % were females; 30.1 % were white, 14.8 % black, 28.7 % Hispanic, 6.1 % Asian and 18.2 % other/unknown race/ethnicity. Median values of Hp (47.9 vs 12.6 U/mL, p = 0.003) and pepsinogen ratio (PGR=PGI/PGII) (4.0 vs 7.5, p = 0.003) differed between GC and non-GC. Performance of pepsinogen tests using “standard” cut-offs (PGI ≤ 70 ng/mL and PGR ≤ 3) were highly specific (91.7 %), but not sensitive (34.4 %), while Hp IgG test using “standard” cut-off (≥ 30 U/mL) was sensitive (78.8 %), but less specific (41.2 %). Optimized cut-off values identified in our population using Youden’s Index were PGR ≤ 5.2 and Hp ≥ 17.5 U/mL. Using a combination of these values resulted in a significant increase in test sensitivity (87.9 %) with lower specificity (50.8 %).</p></div><div><h3>Conclusion</h3><p>The combination of pepsinogens and Hp show promise as biomarkers of GC risk in a racially and ethnically diverse US population. Optimal biomarker cut-off points for US populations may differ from those established in East Asia. By adjusting cut-offs there is potential to design GC risk stratification tools tailored specifically for the diverse population within the US.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000951/pdfft?md5=e7731a8c74fbbf81ed7ca9176c736bcd&pid=1-s2.0-S2950247024000951-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-30DOI: 10.1016/j.soi.2024.100094
Nina Morena , Libby Ben-Zvi , Victoria Hayman , Mary Hou , Andrew Gorgy , Diana Nguyen , Carrie A. Rentschler , Ari N. Meguerditchian
Background
Social media platforms are a significant source of information for young women with breast cancer (YWBC) undergoing post-mastectomy breast reconstruction (PMBR). The emphasis on visual storytelling and building community in online spaces renders YouTube to be a common platform for discussions of BR. This study aims to assess the quality of YouTube videos about PMBR, identify themes related to the PMBR experience, and quantify suggestions of BR as an option PM.
Methods
YouTube was searched incognito with terms “young women breast cancer reconstruction” in 08/2022, in order from most to least viewed. Title, upload date, length, poster identity, number of likes and comments were collected. The Patient Education Materials Assessment Tool for audiovisual materials (PEMAT A/V) was used to evaluate understandability and actionability. DISCERN assessed quality and reliability. Presence of sponsorship, intended audience, patient and healthcare professional narratives, and suggestions of PMBR were collected. Reviewers noted whether PMBR was shown and how. Themes were collected inductively and deductively for thematic analysis.
Results
193 videos were identified. Mean video length was 14.6 min (SD 20.0 min). 87.1 % included sponsorships. 95.9 % of videos were posted by an organization. 60.6 % were information-based; 45.6 % experience-based. Mean PEMAT scores for understandability and actionability were 71.3 % (SD 13.4) and 35.7 % (SD 41.8), respectively. Mean DISCERN was 2.6/5 (SD 1.2). Patient narrative was present in 52.6 % and healthcare professionals’ in 68.4 %. PMBR was visually presented 22.8 % of the time. 13.5 % of videos explicitly recommended PMBR. 2.6 % explicitly discouraged it. Patients (77.7 %) represented the majority of the intended audience. Most common deductively identified themes included treatment (87.1 %), family relationship (17.1 %), motherhood (15.5 %), fertility (11.9 %). Inductively identified subthemes included differentiating between various options for PMBR surgery, BRCA genetic testing, psychosocial effects of breast cancer and PMBR, and recovery from surgery.
Conclusion
YouTube is a platform wherein various PMBR options are widely discussed and explained. PMBR videos are highly understandable but have moderate levels of actionability, quality, and reliability. Videos are highly sponsored, demonstrating significant institutional bias. Themes are overwhelmingly treatment and surgery-based. Personal themes were present but not dominant.
{"title":"How reliable are post-mastectomy breast reconstruction videos on YouTube?","authors":"Nina Morena , Libby Ben-Zvi , Victoria Hayman , Mary Hou , Andrew Gorgy , Diana Nguyen , Carrie A. Rentschler , Ari N. Meguerditchian","doi":"10.1016/j.soi.2024.100094","DOIUrl":"10.1016/j.soi.2024.100094","url":null,"abstract":"<div><h3>Background</h3><p>Social media platforms are a significant source of information for young women with breast cancer (YWBC) undergoing post-mastectomy breast reconstruction (PMBR). The emphasis on visual storytelling and building community in online spaces renders YouTube to be a common platform for discussions of BR. This study aims to assess the quality of YouTube videos about PMBR, identify themes related to the PMBR experience, and quantify suggestions of BR as an option PM.</p></div><div><h3>Methods</h3><p>YouTube was searched incognito with terms “young women breast cancer reconstruction” in 08/2022, in order from most to least viewed. Title, upload date, length, poster identity, number of likes and comments were collected. The Patient Education Materials Assessment Tool for audiovisual materials (PEMAT A/V) was used to evaluate understandability and actionability. DISCERN assessed quality and reliability. Presence of sponsorship, intended audience, patient and healthcare professional narratives, and suggestions of PMBR were collected. Reviewers noted whether PMBR was shown and how. Themes were collected inductively and deductively for thematic analysis.</p></div><div><h3>Results</h3><p>193 videos were identified. Mean video length was 14.6 min (SD 20.0 min). 87.1 % included sponsorships. 95.9 % of videos were posted by an organization. 60.6 % were information-based; 45.6 % experience-based. Mean PEMAT scores for understandability and actionability were 71.3 % (SD 13.4) and 35.7 % (SD 41.8), respectively. Mean DISCERN was 2.6/5 (SD 1.2). Patient narrative was present in 52.6 % and healthcare professionals’ in 68.4 %. PMBR was visually presented 22.8 % of the time. 13.5 % of videos explicitly recommended PMBR. 2.6 % explicitly discouraged it. Patients (77.7 %) represented the majority of the intended audience. Most common deductively identified themes included treatment (87.1 %), family relationship (17.1 %), motherhood (15.5 %), fertility (11.9 %). Inductively identified subthemes included differentiating between various options for PMBR surgery, BRCA genetic testing, psychosocial effects of breast cancer and PMBR, and recovery from surgery.</p></div><div><h3>Conclusion</h3><p>YouTube is a platform wherein various PMBR options are widely discussed and explained. PMBR videos are highly understandable but have moderate levels of actionability, quality, and reliability. Videos are highly sponsored, demonstrating significant institutional bias. Themes are overwhelmingly treatment and surgery-based. Personal themes were present but not dominant.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001038/pdfft?md5=62a065ee51c87e594bdcc2000e6131dc&pid=1-s2.0-S2950247024001038-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-30DOI: 10.1016/j.soi.2024.100092
Vladislav Kovalik, Mary Caitlin King, Sergei Iugai, Luis Felipe Falla-Zuniga, Carol Nieroda, Armando Sardi, Vadim Gushchin
Background
Inflammatory bowel disease (IBD) may compromise outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal metastases (PM) from appendix/colon cancer. We evaluated CRS/HIPEC outcomes in patients with concurrent IBD.
Methods
A matched cohort study using a prospective institutional CRS/HIPEC database (1998–2023) included appendix/colon cancer patients with PM. We matched IBD patients to IBD-free controls in a 1:5 ratio with nearest-neighbor propensity score for sex, age, and peritoneal cancer index (PCI), and exact matching for prior CRS/HIPEC and primary tumor. Perioperative variables, including Clavien-Dindo 90-day complications, were compared. Kaplan-Meier overall (OS) and progression-free survival (PFS) were compared using stratified Cox regression.
Results
Of 605 CRS/HIPECs for appendix/colon cancer, 14 (2.3%) had concurrent Crohn’s disease (n = 6) or ulcerative colitis (n = 8). Seventy IBD-free controls were matched. Nine (64.7%) IBD patients had an appendix primary. Complete cytoreduction (CC-0/1) was achieved in 10 (71.4%) IBD and 57 (81.4%) IBD-free patients (p = 0.468). IBD vs IBD-free patients tended to have more grade-III/IV complications (35.7% [n = 5] vs 15.7% [n = 11], p = 0.082) and had a higher rate of severe nausea/vomiting (35.7% vs 4.3 %, p < 0.001) and diarrhea (28.6% vs 8.6%, p = 0.035). Rates of anastomotic leak (7.1% [n = 1] vs 1.4% [n = 1], p = 0.200) and intraabdominal infections (7.1% [n = 1] vs 2.9% [n = 2], p = 0.430) were similar for IBD vs IBD-free, respectively. IBD did not affect OS (HR [95% CI]: 1.1 [0.4, 2.9]) or PFS (HR [95% CI]: 1.2 [0.4, 3.9]).
Conclusion
IBD is associated with a higher rate of gastrointestinal complications after CRS/HIPEC for appendix/colon cancer; however, it does not affect OS or PFS.
{"title":"Surgical management of peritoneal metastases from appendix and colon cancer in patients with inflammatory bowel disease","authors":"Vladislav Kovalik, Mary Caitlin King, Sergei Iugai, Luis Felipe Falla-Zuniga, Carol Nieroda, Armando Sardi, Vadim Gushchin","doi":"10.1016/j.soi.2024.100092","DOIUrl":"10.1016/j.soi.2024.100092","url":null,"abstract":"<div><h3>Background</h3><p>Inflammatory bowel disease (IBD) may compromise outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal metastases (PM) from appendix/colon cancer. We evaluated CRS/HIPEC outcomes in patients with concurrent IBD.</p></div><div><h3>Methods</h3><p>A matched cohort study using a prospective institutional CRS/HIPEC database (1998–2023) included appendix/colon cancer patients with PM. We matched IBD patients to IBD-free controls in a 1:5 ratio with nearest-neighbor propensity score for sex, age, and peritoneal cancer index (PCI), and exact matching for prior CRS/HIPEC and primary tumor. Perioperative variables, including Clavien-Dindo 90-day complications, were compared. Kaplan-Meier overall (OS) and progression-free survival (PFS) were compared using stratified Cox regression.</p></div><div><h3>Results</h3><p>Of 605 CRS/HIPECs for appendix/colon cancer, 14 (2.3%) had concurrent Crohn’s disease (n = 6) or ulcerative colitis (n = 8). Seventy IBD-free controls were matched. Nine (64.7%) IBD patients had an appendix primary. Complete cytoreduction (CC-0/1) was achieved in 10 (71.4%) IBD and 57 (81.4%) IBD-free patients (p = 0.468). IBD vs IBD-free patients tended to have more grade-III/IV complications (35.7% [n = 5] vs 15.7% [n = 11], p = 0.082) and had a higher rate of severe nausea/vomiting (35.7% vs 4.3 %, p < 0.001) and diarrhea (28.6% vs 8.6%, p = 0.035). Rates of anastomotic leak (7.1% [n = 1] vs 1.4% [n = 1], p = 0.200) and intraabdominal infections (7.1% [n = 1] vs 2.9% [n = 2], p = 0.430) were similar for IBD vs IBD-free, respectively. IBD did not affect OS (HR [95% CI]: 1.1 [0.4, 2.9]) or PFS (HR [95% CI]: 1.2 [0.4, 3.9]).</p></div><div><h3>Conclusion</h3><p>IBD is associated with a higher rate of gastrointestinal complications after CRS/HIPEC for appendix/colon cancer; however, it does not affect OS or PFS.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001014/pdfft?md5=5d30dbe9e2d5373a8c1c9cac5f48d2f9&pid=1-s2.0-S2950247024001014-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-25DOI: 10.1016/j.soi.2024.100093
Jaclyn A. Gellings , Chandler S. Cortina , Julie Kijak , Julie Bradley , Mohammed Aldakkak , Carmen Bergom , Amanda L. Kong
Factors associated with selection of proton therapy (PT) or intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation in breast cancer were evaluated. As PT usage increases, data on local control, survival, long-term sequelae, and patient-reported outcomes of PT vs photon therapy are important to guide optimal application of radiation techniques.
{"title":"Adjuvant breast radiation therapy practice patterns in the United States from 2012–2017","authors":"Jaclyn A. Gellings , Chandler S. Cortina , Julie Kijak , Julie Bradley , Mohammed Aldakkak , Carmen Bergom , Amanda L. Kong","doi":"10.1016/j.soi.2024.100093","DOIUrl":"10.1016/j.soi.2024.100093","url":null,"abstract":"<div><p>Factors associated with selection of proton therapy (PT) or intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation in breast cancer were evaluated. As PT usage increases, data on local control, survival, long-term sequelae, and patient-reported outcomes of PT vs photon therapy are important to guide optimal application of radiation techniques.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001026/pdfft?md5=1aea204f46e9b6050913330630a9d023&pid=1-s2.0-S2950247024001026-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-22DOI: 10.1016/j.soi.2024.100091
Ryan A. Denu , Christopher D. Quintana-Perez , Sintawat Wangsiricharoen , Davis R. Ingram , Khalida M. Wani , Alexander J. Lazar , Ravin Ratan , Christina L. Roland , Y. Nancy You
Purpose
Lynch syndrome (LS) is a cancer predisposition syndrome caused by a germline loss-of-function mutation in a mismatch repair (MMR) gene. While sarcomas are not classically considered LS cancers, we investigated the MMR status and clinical features of sarcomas in LS patients to help inform optimal treatment strategies.
Methods
A prospectively maintained institutional clinical cancer genetics database was queried for LS patients (defined by pathogenic germline mutation in a MMR gene) with a documented diagnosis of sarcoma between 1998–2022. Tumor MMR status was determined by immunohistochemistry (IHC) for MMR proteins and secondarily by PCR assay if IHC was normal or intact.
Results
Among the 30 LS patients with sarcoma, germline mutations were most common in MSH2 (50 %). The most common sarcoma subtypes were undifferentiated pleomorphic sarcoma (40 %) and leiomyosarcoma (27 %). Median age at diagnosis was 49.2 years (interquartile range 40.4–62.4). 90 % presented with localized disease, and 10 % presented with synchronous metastatic disease. Among 10 patients with tissue available for biomarker determination, dMMR was confirmed in 4 (40 %), while the remaining (60 %) were pMMR. Three patients received immunotherapy. Two of these had confirmed dMMR tumor status: one demonstrated a sustained complete response on pembrolizumab monotherapy for 44 months; the other had a partial response on ipilimumab and nivolumab for 31 months but died from an unrelated cause. In the entire cohort of 30 patients at a median follow-up time of 68.2 months since sarcoma diagnosis (interquartile range 29.0–151.5 months), median overall survival and progression-free survival have not been reached.
Conclusion
While rare, sarcoma can be encountered in patients with LS, particularly those with germline MSH2 mutation. LS-associated sarcomas occur significantly earlier, carry a favorable outcome, and demonstrate the potential for durable response with immunotherapy.
{"title":"DNA mismatch repair deficiency as a biomarker in sarcoma","authors":"Ryan A. Denu , Christopher D. Quintana-Perez , Sintawat Wangsiricharoen , Davis R. Ingram , Khalida M. Wani , Alexander J. Lazar , Ravin Ratan , Christina L. Roland , Y. Nancy You","doi":"10.1016/j.soi.2024.100091","DOIUrl":"10.1016/j.soi.2024.100091","url":null,"abstract":"<div><h3>Purpose</h3><p>Lynch syndrome (LS) is a cancer predisposition syndrome caused by a germline loss-of-function mutation in a mismatch repair (MMR) gene. While sarcomas are not classically considered LS cancers, we investigated the MMR status and clinical features of sarcomas in LS patients to help inform optimal treatment strategies.</p></div><div><h3>Methods</h3><p>A prospectively maintained institutional clinical cancer genetics database was queried for LS patients (defined by pathogenic germline mutation in a MMR gene) with a documented diagnosis of sarcoma between 1998–2022. Tumor MMR status was determined by immunohistochemistry (IHC) for MMR proteins and secondarily by PCR assay if IHC was normal or intact.</p></div><div><h3>Results</h3><p>Among the 30 LS patients with sarcoma, germline mutations were most common in <em>MSH2</em> (50 %). The most common sarcoma subtypes were undifferentiated pleomorphic sarcoma (40 %) and leiomyosarcoma (27 %). Median age at diagnosis was 49.2 years (interquartile range 40.4–62.4). 90 % presented with localized disease, and 10 % presented with synchronous metastatic disease. Among 10 patients with tissue available for biomarker determination, dMMR was confirmed in 4 (40 %), while the remaining (60 %) were pMMR. Three patients received immunotherapy. Two of these had confirmed dMMR tumor status: one demonstrated a sustained complete response on pembrolizumab monotherapy for 44 months; the other had a partial response on ipilimumab and nivolumab for 31 months but died from an unrelated cause. In the entire cohort of 30 patients at a median follow-up time of 68.2 months since sarcoma diagnosis (interquartile range 29.0–151.5 months), median overall survival and progression-free survival have not been reached.</p></div><div><h3>Conclusion</h3><p>While rare, sarcoma can be encountered in patients with LS, particularly those with germline <em>MSH2</em> mutation. LS-associated sarcomas occur significantly earlier, carry a favorable outcome, and demonstrate the potential for durable response with immunotherapy.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001002/pdfft?md5=ab6d50594cef0801f725d56e6a363e9b&pid=1-s2.0-S2950247024001002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-12DOI: 10.1016/j.soi.2024.100090
Kevin Verhoeff , Juan Glinka , Douglas Quan , Ephraim S. Tang , Anton Skaro
Background
Comparison of laparoscopic (LPD) and robotic (RPD) pancreaticoduodenectomy over time remains limited. This study aims to compare LPD and RPD and to describe the demographics and outcomes of patients undergoing MIS pancreaticoduodenectomy over 5-years.
Methods
The ACS-NSQIP (2016–2021) database was used to evaluate patients undergoing MIS pancreaticoduodenectomy comparing LPD versus RPD. Patient characteristics, and outcomes were compared and multivariable modelling evaluated factors associated with serious complications, and mortality. MIS approach, demographics, and outcomes were assessed yearly to evaluate trends over time.
Results
We evaluated 1707 patients with 1148 (67.3 %) receiving RPD. Cohorts were similar with regards to demographic factors, however, patients undergoing RPD were less likely to be partially dependent (0.5 % vs. 1.6 %; p = 0.024), and more likely to receive neoadjuvant therapy (26.8 % vs. 21.7 %; p = 0.023).
Bivariate analysis demonstrated similar operative duration (444.1 vs 429.9 min; p = 0.074), but shorter LOS (8.5 vs. 9.8 days; p < 0.001), and higher readmission rate (21.5 % vs. 15.6 %; p = 0.004) with RPD. Additionally, RPD required transfusion less often (10.5 % vs. 21.7 %; p < 0.001). Multivariable analysis demonstrated that LPD was not independently associated with serious complications (OR 1.27 p = 0.094) or mortality (OR 0.82, p = 0.611).
Analysis of trends from 2016 to 2021 demonstrated similar patient selection and outcomes but a significant increase in MIS pancreaticoduodenectomy (281 to 428), primarily driven by an increase in RPD.
Conclusions
Comparing LPD and RPD there is no difference in serious complications or mortality. MIS pancreaticoduodenectomy has increased over the last 5 years but volumes remain small with similar demographics and outcomes over time.
背景腹腔镜(LPD)和机器人(RPD)胰十二指肠切除术的长期比较仍然有限。本研究旨在对LPD和RPD进行比较,并描述5年内接受MIS胰十二指肠切除术的患者的人口统计学特征和预后。比较了患者特征和预后,并通过多变量模型评估了与严重并发症和死亡率相关的因素。每年对 MIS 方法、人口统计学和结果进行评估,以评估随时间变化的趋势。 结果我们评估了 1707 例患者,其中 1148 例(67.3%)接受了 RPD。人群的人口统计学因素相似,但接受RPD的患者部分依赖的可能性较低(0.5 % vs. 1.6 %; p = 0.024),接受新辅助治疗的可能性较高(26.8 % vs. 21.双变量分析显示,RPD 的手术时间相似(444.1 分钟 vs 429.9 分钟;p = 0.074),但 LOS 更短(8.5 天 vs 9.8 天;p < 0.001),再入院率更高(21.5% vs 15.6%;p = 0.004)。此外,RPD 需要输血的次数较少(10.5% 对 21.7%;p = 0.001)。多变量分析表明,LPD与严重并发症(OR 1.27,p = 0.094)或死亡率(OR 0.82,p = 0.611)无独立关联。对2016年至2021年的趋势分析表明,患者选择和结果相似,但MIS胰十二指肠切除术显著增加(从281例增至428例),主要是由于RPD的增加。MIS胰十二指肠切除术在过去5年中有所增加,但手术量仍然很小,人口统计学和手术结果与过去相似。
{"title":"Laparoscopic versus robotic pancreaticoduodenectomy: A NSQIP analysis comparing trends in patient selection and outcomes over 5-years","authors":"Kevin Verhoeff , Juan Glinka , Douglas Quan , Ephraim S. Tang , Anton Skaro","doi":"10.1016/j.soi.2024.100090","DOIUrl":"10.1016/j.soi.2024.100090","url":null,"abstract":"<div><h3>Background</h3><p>Comparison of laparoscopic (LPD) and robotic (RPD) pancreaticoduodenectomy over time remains limited. This study aims to compare LPD and RPD and to describe the demographics and outcomes of patients undergoing MIS pancreaticoduodenectomy over 5-years.</p></div><div><h3>Methods</h3><p>The ACS-NSQIP (2016–2021) database was used to evaluate patients undergoing MIS pancreaticoduodenectomy comparing LPD versus RPD. Patient characteristics, and outcomes were compared and multivariable modelling evaluated factors associated with serious complications, and mortality. MIS approach, demographics, and outcomes were assessed yearly to evaluate trends over time.</p></div><div><h3>Results</h3><p>We evaluated 1707 patients with 1148 (67.3 %) receiving RPD. Cohorts were similar with regards to demographic factors, however, patients undergoing RPD were less likely to be partially dependent (0.5 % vs. 1.6 %; p = 0.024), and more likely to receive neoadjuvant therapy (26.8 % vs. 21.7 %; p = 0.023).</p><p>Bivariate analysis demonstrated similar operative duration (444.1 vs 429.9 min; p = 0.074), but shorter LOS (8.5 vs. 9.8 days; p < 0.001), and higher readmission rate (21.5 % vs. 15.6 %; p = 0.004) with RPD. Additionally, RPD required transfusion less often (10.5 % vs. 21.7 %; p < 0.001). Multivariable analysis demonstrated that LPD was not independently associated with serious complications (OR 1.27 p = 0.094) or mortality (OR 0.82, p = 0.611).</p><p>Analysis of trends from 2016 to 2021 demonstrated similar patient selection and outcomes but a significant increase in MIS pancreaticoduodenectomy (281 to 428), primarily driven by an increase in RPD.</p></div><div><h3>Conclusions</h3><p>Comparing LPD and RPD there is no difference in serious complications or mortality. MIS pancreaticoduodenectomy has increased over the last 5 years but volumes remain small with similar demographics and outcomes over time.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000999/pdfft?md5=c3a7ec9b70f7781d545673aca06a054e&pid=1-s2.0-S2950247024000999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-10DOI: 10.1016/j.soi.2024.100089
Yannick Albert J. Hoftiezer , Floris V. Raasveld , Joseph O. Werenski , H.W.B. Schreuder Bart , Dietmar J.O. Ulrich , E.P.A. van der Heijden Brigitte , Kyle R. Eberlin , Santiago A. Lozano-Calderón
Background
Neurovascular involvement of extremity neoplasms is historically considered a contraindication for limb-salvage surgery, due to concerns of limb dysfunction secondary to motor and/or sensory loss. Theoretically, large nerve defects may be amenable to reconstruction using grafts, but the outcomes of these techniques in irradiated oncologic patients remain unclear.
Methods
This study investigates reconstruction of oncologic nerve defects in the extremities in patients who underwent (neo)adjuvant radiotherapy. A retrospective series of ten patients with extremity sarcoma is provided, with six lower extremity and four upper extremity cases. Reconstruction consisted of nerve grafting with or without the addition of tendon transfers. The mean duration of clinical follow-up was 42.5 months.
Results
Nerve graft reconstruction led to recovery of motor or sensory function in eight out of ten patients thereby allowing functional limb preservation, with none of the patients developing significant neuropathic pain, a common complication in oncologic resections of the extremities with nerve involvement or following amputation. Thus, radiotherapy does not seem to completely preclude successful graft reconstruction of large oncologic extremity nerve defects.
Conclusions
Although the oncologic disease itself is associated with significant mortality, the results of the nerve reconstruction were encouraging despite the concomitant use of radiation. Based on the available data and literature, we recommend to at least discuss the option of graft-based nerve reconstruction with affected patients if relevant characteristics such as patient comorbidities and the viability of recipient muscle are favorable.
Synopsis
In this study, the results of nerve graft reconstruction of large sarcoma-related nerve defects were evaluated. This type of reconstruction seems feasible even in irradiated limbs, thereby aiding in functional limb preservation.
{"title":"Nerve graft reconstruction of irradiated oncologic segmental nerve defects in the extremities: A case series","authors":"Yannick Albert J. Hoftiezer , Floris V. Raasveld , Joseph O. Werenski , H.W.B. Schreuder Bart , Dietmar J.O. Ulrich , E.P.A. van der Heijden Brigitte , Kyle R. Eberlin , Santiago A. Lozano-Calderón","doi":"10.1016/j.soi.2024.100089","DOIUrl":"10.1016/j.soi.2024.100089","url":null,"abstract":"<div><h3>Background</h3><p>Neurovascular involvement of extremity neoplasms is historically considered a contraindication for limb-salvage surgery, due to concerns of limb dysfunction secondary to motor and/or sensory loss. Theoretically, large nerve defects may be amenable to reconstruction using grafts, but the outcomes of these techniques in irradiated oncologic patients remain unclear.</p></div><div><h3>Methods</h3><p>This study investigates reconstruction of oncologic nerve defects in the extremities in patients who underwent (neo)adjuvant radiotherapy. A retrospective series of ten patients with extremity sarcoma is provided, with six lower extremity and four upper extremity cases. Reconstruction consisted of nerve grafting with or without the addition of tendon transfers. The mean duration of clinical follow-up was 42.5 months.</p></div><div><h3>Results</h3><p>Nerve graft reconstruction led to recovery of motor or sensory function in eight out of ten patients thereby allowing functional limb preservation, with none of the patients developing significant neuropathic pain, a common complication in oncologic resections of the extremities with nerve involvement or following amputation. Thus, radiotherapy does not seem to completely preclude successful graft reconstruction of large oncologic extremity nerve defects.</p></div><div><h3>Conclusions</h3><p>Although the oncologic disease itself is associated with significant mortality, the results of the nerve reconstruction were encouraging despite the concomitant use of radiation. Based on the available data and literature, we recommend to at least discuss the option of graft-based nerve reconstruction with affected patients if relevant characteristics such as patient comorbidities and the viability of recipient muscle are favorable.</p></div><div><h3>Synopsis</h3><p>In this study, the results of nerve graft reconstruction of large sarcoma-related nerve defects were evaluated. This type of reconstruction seems feasible even in irradiated limbs, thereby aiding in functional limb preservation.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100089"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000987/pdfft?md5=30608987aa8614b7fd47e7e85eb7641d&pid=1-s2.0-S2950247024000987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-07DOI: 10.1016/j.soi.2024.100084
Amanda N. Labora, Nimmi S. Kapoor
Ultrasound provides essential diagnostic and therapeutic applications in almost every medical and surgical field. In breast surgery, the importance of ultrasound cannot be overstated as it plays a critical role in both radiographic and tissue diagnosis, and can be used to guide surgical resection. Newer, cheaper, and more portable ultrasounds facilitate its use in the clinic and the operating room, making it a cost-effective, patient-centered tool in the management of benign and malignant breast conditions. This paper provides an overview of the evolution of breast ultrasound in surgical practice, its potential underuse in surgery, and explores emerging applications in breast surgery. Lastly, we identify opportunities for improvement in education, training, and access to ultrasound to overcome some of the barriers to ultrasound use by surgeons.
{"title":"The evolution of breast ultrasound in surgical practice: Current applications, missed opportunities, and future directions","authors":"Amanda N. Labora, Nimmi S. Kapoor","doi":"10.1016/j.soi.2024.100084","DOIUrl":"10.1016/j.soi.2024.100084","url":null,"abstract":"<div><p>Ultrasound provides essential diagnostic and therapeutic applications in almost every medical and surgical field. In breast surgery, the importance of ultrasound cannot be overstated as it plays a critical role in both radiographic and tissue diagnosis, and can be used to guide surgical resection. Newer, cheaper, and more portable ultrasounds facilitate its use in the clinic and the operating room, making it a cost-effective, patient-centered tool in the management of benign and malignant breast conditions. This paper provides an overview of the evolution of breast ultrasound in surgical practice, its potential underuse in surgery, and explores emerging applications in breast surgery. Lastly, we identify opportunities for improvement in education, training, and access to ultrasound to overcome some of the barriers to ultrasound use by surgeons.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000938/pdfft?md5=cea31fbc3328ea308b3dae0a09ab9553&pid=1-s2.0-S2950247024000938-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141952898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-07DOI: 10.1016/j.soi.2024.100085
Jamila Alazhri , Eman Hamza , Fozan Aldulaijan , Sarah Alajmi , Elinor Doherty , Lebogangk Tafangombe , Eithne Downey , Aishling Hegarty , Abeeda Butt , Arnold Hill
Introduction
Axillary surgery has been de-escalated in invasive breast carcinoma and may be omitted in certain age groups. Up to 10–20 % of patients with ductal carcinoma in-situ (DCIS) will have an element of invasion. Therefore, SLNB is indicated to rule out nodal metastasis. Our purpose was to identify the rate and possible risk factors for lymph node metastasis in DCIS, and to measure oncological outcome of positive SLNB in this group.
Methods
A retrospective analysis was performed on 113 female patients with DCIS, who underwent mastectomy and SLNB. Their clinical and radiological features, as well as pre and post-operative histopathological characteristics were evaluated and data was reported over an average follow up period of 48 months.
Result
DCIS was upgraded to invasive cancer in 11 patients out of 113 (9.7 %). Five patients had positive SLNB (4.4 %), one micro-metastasis (0.8 %) and four macro-metastasis (3.5 %) All the five underwent axillary lymph node dissection (ALND) and all additional nodes retrieved were negative. High nuclear grade, Her2 neu overexpression, and palpable mass showed higher odds of association with metastasis to sentinel nodes. However, due to the low event rate, the association did not reach statistical significance. Seven patients (6.2 %) developed lymphedema, 4 of which after SLNB only. No regional recurrence was reported among our study sample.
Conclusion
This study confirms the very low rate of positive SLNB in patients with DCIS. It is time to de-escalate axillary surgery for patients with DCIS undergoing mastectomy and consider delayed SLNB for high risk group of patients.
{"title":"Is it time to de-escalate axillary surgery in patients with ductal carcinoma in-situ undergoing mastectomy?","authors":"Jamila Alazhri , Eman Hamza , Fozan Aldulaijan , Sarah Alajmi , Elinor Doherty , Lebogangk Tafangombe , Eithne Downey , Aishling Hegarty , Abeeda Butt , Arnold Hill","doi":"10.1016/j.soi.2024.100085","DOIUrl":"10.1016/j.soi.2024.100085","url":null,"abstract":"<div><h3>Introduction</h3><p>Axillary surgery has been de-escalated in invasive breast carcinoma and may be omitted in certain age groups. Up to 10–20 % of patients with ductal carcinoma in-situ (DCIS) will have an element of invasion. Therefore, SLNB is indicated to rule out nodal metastasis. Our purpose was to identify the rate and possible risk factors for lymph node metastasis in DCIS, and to measure oncological outcome of positive SLNB in this group.</p></div><div><h3>Methods</h3><p>A retrospective analysis was performed on 113 female patients with DCIS, who underwent mastectomy and SLNB. Their clinical and radiological features, as well as pre and post-operative histopathological characteristics were evaluated and data was reported over an average follow up period of 48 months.</p></div><div><h3>Result</h3><p>DCIS was upgraded to invasive cancer in 11 patients out of 113 (9.7 %). Five patients had positive SLNB (4.4 %), one micro-metastasis (0.8 %) and four macro-metastasis (3.5 %) All the five underwent axillary lymph node dissection (ALND) and all additional nodes retrieved were negative. High nuclear grade, Her2 neu overexpression, and palpable mass showed higher odds of association with metastasis to sentinel nodes. However, due to the low event rate, the association did not reach statistical significance. Seven patients (6.2 %) developed lymphedema, 4 of which after SLNB only. No regional recurrence was reported among our study sample.</p></div><div><h3>Conclusion</h3><p>This study confirms the very low rate of positive SLNB in patients with DCIS. It is time to de-escalate axillary surgery for patients with DCIS undergoing mastectomy and consider delayed SLNB for high risk group of patients.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100085"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295024702400094X/pdfft?md5=3956d534d5a0d91ec22c3d83c1aa4ec5&pid=1-s2.0-S295024702400094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}